Trial Profile
A Phase 2 Study to Assess the Safety and Immunogenicity of an A (H1N1) 2009 Influenza Virus-like Particle (VLP) Vaccine.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Influenza A virus H1N1 vaccine CPL Biologicals (Primary)
- Indications Influenza A virus H1N1 subtype
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors Novavax
- 24 Apr 2012 Actual end date (March 2012) added as reported by ClinicalTrials.gov.
- 24 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 21 Mar 2012 Planned End Date changed from 1 Oct 2010 to 1 Mar 2012 as reported by ClinicalTrials.gov.